Related Experiment Videos
Defining the protective antibody response for HIV-1
1Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892, USA. jmascola@nih.gov
Current Molecular Medicine
|April 18, 2003
Summary
Developing an effective HIV-1 vaccine requires understanding protective antibodies. Animal models show neutralizing antibodies can prevent infection, guiding strategies to induce these antibodies in humans.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Establishing definitive immune correlates for vaccine efficacy is challenging.
- Animal models are crucial for guiding HIV-1 vaccine development.
- Non-human primate lentivirus infection models provide insights into protective immunity.
Purpose of the Study:
- To review the role of neutralizing antibodies in protection against HIV-1 infection.
- To analyze quantitative data from animal models on protective antibody levels.
- To inform HIV-1 vaccine strategies based on antibody-mediated protection.
Main Methods:
- Review of experimental lentivirus infection studies in non-human primates.
- Analysis of passive antibody transfer data in the SIV/HIV-1 immunodeficiency virus (SHIV) model.
- Evaluation of findings from lentiviral animal models regarding antibody function.
Main Results:
- Neutralizing antibodies can protect against lentiviral infection in animal models.
- Passive antibody transfer studies provide quantitative data on protective antibody levels.
- High antibody levels are needed for complete protection, but partial protection and disease modification are possible with lower levels.
Conclusions:
- Neutralizing antibodies are expected to contribute to protection against HIV-1.
- Inducing neutralizing antibodies against circulating HIV-1 strains is a key vaccine strategy.
- Further research is needed to understand antibody complexity in active immunization settings.